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(DCE). METHODS: A discrete-event state-transition model was
developed to estimate the cost-effectiveness of all scenarios for all
patient groups. In addition, a discrete choice experiment (DCE)
was designed to establish patient preferences. The DCE incorpo-
rated three process attributes (duration of follow-up, frequency
and type of consult) and data were collected in a sample of 125
breast cancer patients. Patients had to complete all 18 choice sets
that were generated from the three attributes. RESULTS: The
modelling study revealed recommendations for follow-up in dif-
ferent age categories. Patients younger than 40 and patients with
unfavorable tumor characteristics (>3 lymph nodes, tumor size
>2 cm) can beneﬁt from a more intensive follow-up of ﬁve or
possibly ten years. Patients older than 40 but younger than 70
years old sometimes beneﬁt from a more intensive follow-up; e.g.
when younger than 50 and tumor size >2 cm. The DCE, however,
showed that patients chose maximum levels of follow-up inde-
pendent from age and their individual clinical risk proﬁle. Dura-
tion of follow-up and type of consult (either hospital visit or
telephone) weighted approximately 0.43 and 0.50 respectively.
The frequency of follow-up (either once or twice a year) was least
important (0.07). CONCLUSIONS: The model showed that
follow-up may be individualized according to risk proﬁle and
age. However, patients preferred long and intensive follow-up
strategies after breast cancer treatment. Taking into account indi-
vidual patient preferences it may be recommended to reduce the
frequency of follow-up to once a year. The service delivery by
nurse practioners is well appreciated and another means for
improving cost-effective follow-up.
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OBJECTIVES: In France, expensive innovative drugs are paid
by health insurance over and above per-case payments to hos-
pitals. Health authorities and pharmaceutical companies set a
ceiling price. Hospitals are encouraged to negotiate cheaper
prices and receive bonus payments equal to half of the differ-
ence. We assessed the impact of policy decisions about Taxanes
(Paclitaxel and Docetaxel) on the costs of breast cancer drugs,
both for health insurance and hospitals, on the turnover of
pharmaceutical companies and on the behaviours of these three
stakeholders. METHODS: We conducted 1) a retrospective
observational study to determine the resources allocated to che-
motherapy drugs in an actual clinical setting, and 2) a prospec-
tive study simulating stakeholders’ behaviours using clinical
evaluations of Taxanes, results of French epidemiological and
drug use studies and published drug prices. We assessed the
impact of 1) decreasing the ceiling price of Paclitaxel by 50%,
and 2) excluding Paclitaxel from the list of expensive innova-
tive drugs. RESULTS: Baseline economic data for drug use in
breast cancer are: €369 million expenditure for health insur-
ance; €0.73 million savings for hospitals, especially because of
the bonus payments; and €366 million turnover of pharmaceu-
tical companies. Decreasing the ceiling price of Paclitaxel has
an impact on hospitals who then might substitute Paclitaxel to
Docetaxel, but the manufacturer of Docetaxel can get the
market back by lowering actual price by 3%. The impact of
excluding Paclitaxel from the list of expensive innovative drugs
is small for health insurance but important for hospitals who
may then substitute Docetaxel to Paclitaxel. This increases
health insurance expenditures and health authorities must then
negotiate a lower ceiling price for Docetaxel. CONCLUSIONS:
Our study shows that policy decisions modify stakeholders’
behaviours, though not always as expected. This approach
could be used in the future for studying other expensive inno-
vative drugs.
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OBJECTIVES: A web-based survey was designed to conﬁrm time
and activities associated with mucositis management for
US-based radiation oncology staff treating HNC patients at dif-
ferent treatment stages. This study examined some of the respon-
dent and practice characteristics that were observed to be
associated with the mucositis management time. METHODS:
Respondents completing the survey were required to be either
licensed physicians (n = 50) treating at least 3 HNC patients per
month or RNs (n = 51) actively practicing in a radiation oncol-
ogy facility. The survey was designed after detailed interviews
with four physicians and nurses to identify key activities associ-
ated with mucositis management. Time associated with each task
was analyzed using descriptive statistics and summed to per-
patient per-treatment level. Nonparametric tests (Wilcoxon,
Spearman correlation) were used to explore the association
between respondent and practice characteristics and mucositis
management time by physician and nurse. RESULTS: Physicians
and nurses reported spending a median of 5.7 and 9.0 hours per
HNC patient, respectively, managing mucositis-related activities
from planning to post-treatment. Female physicians reported
spending more than male physicians (9.0 vs. 5.3 hours, p = 0.04),
and non-Caucasian (predominantly Asian) physicians reported
spending more time than Caucasian physicians (6.9 vs. 4.0 hours,
p = 0.03). Further, physician-reported time was signiﬁcantly
associated with total number of all patients treated per month
(r = 0.3, p = 0.04). Similar associations were not observed for
nurse respondents. Respondents’ years of practicing in radiation
oncology, number of HNC patients treated per month, total
number of HNC patients treated in previous two months, type of
facility respondents practicing at (private vs. community-based),
and facility HNC patient/clinician ratio were not associated with
the mucositis management time reported by respondents. CON-
CLUSIONS: The amount of time spent managing mucositis-
related activities for HNC patients receiving RT is substantial.
Physician-reported time varied substantially by gender and race
and was found to be associated with number of patients treated
per month.
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OBJECTIVES: Continuous suppression of the HER2+
(ErbB2+) receptor is an accepted treatment strategy for patients
with HER2+ MBC. However, consideration of the evidence base
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is also important when identifying appropriate therapeutic
options for patients who have progressed on trastuzumab (TZ).
This study explores UK treatment patterns for women with
HER2 + MBC who progress while on TZ, and have been previ-
ously treated with an anthracycline and a taxane (A&T).
METHODS: Case histories from 2815 women with MBC seen
January 2006 to December 2007 were retrieved from the IMS
Advanced Disease Analyzer database: 421 had received TZ in the
metastatic setting. Changes in therapy were used as a proxy for
disease progression; patients receiving TZ monotherapy within
28 days of ending a previous regimen were excluded from this
deﬁnition to ensure that TZ use as a maintenance treatment was
not inappropriately characterised as progression. Therapeutic
regimens received post-progression were characterised for 98
patients who had progressed on TZ. Results were compared with
a UK treatment survey completed by oncologists with a specialist
interest in breast cancer (n = 92). RESULTS: Of the 98 patients
that progressed on TZ, 54 (55.1%) continued receiving a
TZ-containing regimen, most commonly in combination with
capecitabine (n = 21; 21.4%) or vinorelbine (n = 20; 20.4%).
Capecitabine monotherapy was also commonly used (n = 31;
31.6%). Re-challenge with a taxane was uncommon (n = 1;
1.0%). Major regimens received post-progression on TZ, as
identiﬁed from case histories, agreed closely with results from the
treatment survey. CONCLUSIONS: This study demonstrates
that, despite the lack of a robust evidence base in this population,
a high proportion of patients continue to receive a TZ-containing
regimen post-progression. This highlights a clear need for
evidence-based HER2 targeted therapy in a patient population
where effective treatment options are limited.
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OBJECTIVES: The objective of this study was to examine racial
differences in total and prescription related health care costs and
service utilization associated with adjuvant hormonal therapy in
women with primary breast cancer. METHODS: This was a
retrospective cohort study of Medicaid enrollees with hormone
receptor positive breast cancer newly starting adjuvant hor-
monal therapy. The study used North Carolina Medicaid data,
which was linked to the North Carolina Cancer Registry. The
patients were followed for one year after commencing the index
medication (tamoxifen or aromatase inhibitor) to collect the
data on medication utilization, health care costs, hospitalization
and emergency department (ED) visits. RESULTS: In this cohort
of 609 women with primary breast cancer, mean total health
care costs was $14,513.31 (SD = $15,233.17), which did not
differ signiﬁcantly across the racial groups [white = mean (SD)
$15,261.13 ($16,225.15); black = mean (SD) $13,580.61
($13,870.34); p > 0.05]. Overall mean prescription related costs
were $4612.18 (SD = $3509.59) with white patients having a
signiﬁcantly higher costs [mean (SD) = $5000.51 ($3582.29)] as
compared to black patients [mean (SD) = $4127.85 ($3360.83]
(p < 0.05). After controlling for select background variables,
prescription related costs remained signiﬁcantly higher in white
patients [p < 0.05]; however total health care costs did not differ
signiﬁcantly across the racial groups [p > 0.05]. The likelihood
of hospitalization was signiﬁcantly lower by 33% in black
patients as compared to white patients after controlling for select
background variables (p < 0.05). Black race was associated with
a 3% increase in the likelihood of an ED visit; however the
difference was statistically insigniﬁcant (p < 0.05). CONCLU-
SIONS: In this study white patients had lower non-prescription
related costs as a result of lower service utilization. Higher medi-
cation compliance in white patients may drive prescription
related costs upwards but may consequently reduce the total
health care costs.
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OBJECTIVES: Assess the geographical distribution of the
nationally available resources for the diagnosis/treatment of
patients with cancer in Greece, in order to identify disparities in
available capacity between various geographic regions that
impact on the equality of access to effective care. METHODS:
Due to lack of a centralized cancer registry as well as a national
hospital capacity database, there is no record of either cancer
prevalence or hospital capacity to treat cancer per geographic
region. In this light, a questionnaire-based survey was conducted
to all public and private sector hospitals in Greece, in order to
record their capacity to diagnose/treat cancer. Special emphasis
was placed on the recording of oncology clinic beds and chemo-
therapy beds. Data were clustered according to geographical
region (a total of 11 in Greece) and compared to the percentage
of the population in the region, as calculated in the 2001 census.
RESULTS: Major discrepancies were observed in the distribution
of resources in favor of large urban areas. The majority of the
nationally available oncology clinic beds and chemotherapy beds
(61.6% and 56.4% respectively) is located in the district of
Attica, an area where only 32.2% of the total Greek population
resides. Excess clustering above population percentages is
observed in 2 more districts (that include large urban centers, as
well), whereas for 3 districts, mainly rural, accounting in total for
16,3% of the country population, no available beds were
recorded CONCLUSIONS: Clustering of oncology speciﬁc
resources exceeds the spatial concentration pattern of health care
services observed in Greece. Geographical misdistribution is a
major contributor to access inequalities in health. Fair allocation
of resources according to population distribution could contrib-
ute to achieving earlier access to effective health care, thus reduc-
ing the burden of the disease, lowering the cost for seeking
adequate treatment for the household and ensuring equality in
access.
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OBJECTIVES: The Slovak health care system is funded on the
principles of solidarity, non-proﬁtability and plurality in a
system of compulsory health insurance. Slovakia’s GDP is cur-
rently 58% of the EU 15 GDP average, but is forecasted to
reach 80% of the EU 15 GDP average by 2025. A person born
in Slovakia in 2002 can expect to live 73.9 years on average.
Leading disability causes as % of DALY in Slovakia (2002) in
total DALYs for men with malignant neoplasms were 14.4%
and for women 13.5%. METHODS: We have analysed the
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